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Expectations about and experiences with insulin
therapy contribute to diabetes treatment satisfaction
in insulin-naı ¨ve patients with type 2 diabetes
A. N. Naegeli, R. P. Hayes
Introduction
Personal beliefs or perceptions about the likelihood
that certain experiences will occur are referred to as
expectations (1–4) Regardless of how expectations
originate, their relationship with actual experiences
subsequently inﬂuence an individuals’ overall satis-
faction with outcomes (5–7). Numerous studies have
demonstrated positive and negative associations
between patients’ overall satisfaction and their expec-
tations towards and experience with products and⁄or
services (7–13). For example, in a sample of 344
patients, Kumar et al. (7) found that both the
expectations and experiences with newly prescribed
medication signiﬁcantly impacted overall treatment
satisfaction.
Insulin delivery options for patients with diabetes
continue to expand with the development of new
systems that aim to be straightforward, inconspicu-
ous and less painful. Despite these developments,
insulin-naı ¨ve patients with type 2 diabetes are still
reluctant to initiate insulin therapy. Factors, or barri-
ers, contributing to this reluctance include concerns
about the treatment itself, changes to and restrictions
on lifestyle, fear of taking injections, fear of hypo-
glycaemia, fear of weight gain and low self-efﬁcacy
pertaining to the complexity of managing insulin
therapy (14–22). It is recognised that barriers may
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SUMMARY
Aim: The aim of this study was to investigate how patients’ expectations about
and experiences with insulin therapy contribute to diabetes treatment satisfaction.
Methods: The Expectations about Insulin Therapy (EAITQ) and the Experience with
Insulin Therapy Questionnaires (EWITQ) were administered at baseline and end-
point, respectively to insulin-naı ¨ve patients with type 2 diabetes in a randomised
trial comparing treatment algorithms for inhaled insulin. Pearson correlation coefﬁ-
cients were calculated between EAITQ and EWITQ scores, patient characteristics
and patient-reported outcomes measures. Wilcoxon Signed Rank test compared
EAITQ and EWITQ item score distributions. Differences between EAITQ and EWITQ
scores were calculated to categorise patients according to the extent to which
their expectations were met by experiences (i.e. unmet, met, exceeded).
Results: EAITQ and EWITQ data were available for 240 patients (61% male,
mean age 58 years, mean diabetes duration 10 years, mean baseline HbA1c
8.4%). Increasingly positive expectations were signiﬁcantly associated with greater
self-efﬁcacy; greater levels of positive experiences were signiﬁcantly associated
with greater positive expectations, shorter diabetes duration, less symptom distress,
greater well-being, self-efﬁcacy and diabetes treatment satisfaction. Overall,
patients’ experiences with inhaled insulin therapy were signiﬁcantly more positive
than their expectations: 58% patients’ experiences exceeded expectations, 29%
patients’ experiences met expectations and 13% patients’ experiences did not
meet expectations. Post hoc tests indicated that treatment satisfaction scores
differed among these groups (all p < 0.01). Conclusion: Expectations may not
independently impact treatment satisfaction, but the relationship with experiences
signiﬁcantly contributes to it. The EAITQ and EWITQ may be useful tools for
clinicians to better understand patients’ expectations about and experiences with
insulin therapy.
What’s known
Numerous studies have demonstrated positive and
negative associations between patients’ overall
satisfaction and their expectations towards and
experience with products and ⁄ or services. The
expectations of and subsequent experiences
patients have with insulin therapy may be
important determinants of treatment satisfaction,
but these relationships have not been examined in
the initiation of insulin therapy among insulin-naı¨ve
patients with type 2 diabetes, and to our
knowledge no instruments exist to speciﬁcally
assess these relationships.
What’s new
The Expectations about Insulin Therapy
Questionnaire (EAITQ) and the Experience with
Insulin Therapy Questionnaire (EWITQ) were
developed to assess expectations about insulin
therapy and delivery systems and experiences
corresponding to those expectations, respectively.
Use of these questionnaires within clinical practice
may help clinicians manage patients’ treatment
expectations by providing insight into the degree to
which patient expectations about insulin therapy
may be fulﬁlled through their experiences and how
these factors correlate to overall treatment
satisfaction.
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908 doi: 10.1111/j.1742-1241.2010.02363.xhave an impact on the development of patients’
expectations (22). Instruments do exist and are com-
monly used by clinicians in assessing barriers to
insulin therapy; however, patient-reported barriers
have not previously been correlated with subsequent
treatment satisfaction (14). Thus, these instruments
may have limited value in predicting patient treat-
ment satisfaction and potential adherence to insulin
therapy.
The expectations of and subsequent experiences
patients have with insulin therapy may be important
determinants of treatment satisfaction, but these rela-
tionships have not been examined in the initiation of
insulin therapy among insulin-naı ¨ve patients with
type 2 diabetes, and to our knowledge no instru-
ments exist to speciﬁcally assess these relationships.
Therefore, the Experience About Insulin Therapy
Questionnaire (EAITQ) and the Experience with
Insulin Therapy Questionnaire (EWITQ) were devel-
oped to assess expectations about insulin therapy
and delivery systems and experiences corresponding
to those expectations, respectively (23).
A randomised clinical trial comparing the efﬁcacy
and safety of two treatment algorithms for an
inhaled insulin provided the opportunity to adminis-
ter the EAITQ and EWITQ to a sample of insulin-
naı ¨ve patients with type 2 diabetes who subsequently
experienced treatment with an inhaled insulin, and
to address these research questions:
• What are the correlates of expectations about and
experiences with insulin therapy?
• How do an individual patient’s expectations about
insulin therapy differ from his or her experiences
with insulin therapy?
• How does diabetes treatment satisfaction differ
among those individuals whose expectations about
insulin therapy are exceeded by experiences with
insulin therapy, those whose expectations are met by
their experiences, and those whose expectations are
not met by their experiences?
Methods
This was a 6-month clinical trial conducted in 56
clinical sites in Argentina, Austria, Belgium, France,
India, Mexico, Spain and United States. Primary
outcomes from the study have been reported else-
where (24). Analysis of the clinical trial primary
end-points indicated that there was no signiﬁcant
difference between the two treatment groups. There
were no placebo patients in the clinical trial. The
clinical trial was conducted in agreement with the
Declaration of Helsinki and the International Coun-
cil on Harmonization Guidelines to good Clinical
Practice. The protocol was approved by the local
ethics committee or institutional review board. Par-
ticipants provided informed consent prior to partic-
ipation in the study.
Study participants
Individuals with type 2 diabetes of at least 6 months
duration aged 18–100 years were enrolled in the clin-
ical trial. Patients were eligible to participate in the
study if they had not achieved optimal glycemic con-
trol (A1c > 7.0% and £ 10.5% at screening) using
two or more oral antidiabetic medications, were
insulin-naı ¨ve, were non-smokers for at least
6 months prior to study start, and were able to
perform pulmonary function tests per American
Thoracic Society guidelines. The participants in the
study reported herein were those individuals who
completed the clinical trial and for whom EAITQ
and EWITQ data were available both at baseline and
end-point (24 weeks) (24).
Patient-reported outcomes measures
The following self-administered Patient Reported
Outcomes measures (PROs) were administered at
both baseline and study end-point: Diabetes Treat-
ment Satisfaction Questionnaire Status Version
(DTSQs); Hyperglycaemia, Hypoglycaemia and
Psychological subscales of the Diabetes Symptoms
Checklist-Revised (DSC-R); and Well-Being
Questionnaire 12 (W-BQ12). The EAITQ was
administered at baseline prior to any patient educa-
tion or treatment administration and the EWITQ
at end-point.
The DTSQs is an eight-item instrument designed
to assess satisfaction with diabetes treatment (six
items) and perception of both hyperglycaemia and
hypoglycaemia during the past 4 weeks. Scores for
the six satisfaction items are summed for a total sat-
isfaction score ranging from 0 to 36. Higher scores
correspond to greater satisfaction. The perceived
hyperglycaemia and hypoglycaemia items are
analysed individually and scores range from 0 to 6,
with higher scores corresponding to greater percep-
tion of unacceptable high and low blood sugars,
respectively (25).
Diabetes Symptom Checklist-Revised is a 34-item
instrument designed to provide a comprehensive
assessment of diabetes symptom distress during the
past 4 weeks (26). For this study, participants were
administered only the Hyperglycaemia (four items),
Hypoglycaemia (three items) and Psychological
[Fatigue (four items) and Cognitive Distress (four
items)] subscales. Scores range from 0 to 5 with
higher symptom scores corresponding to greater
symptom severity (26).
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of patients with diabetes. It consists of three sub-
scales (Negative Well-Being, Positive Well-Being
and Energy) of four items each containing both
positively worded and negatively worded items. For
the Positive Well-Being and Energy subscales,
higher scores correspond to a greater sense of well-
being; for the Negative Well-Being subscale, higher
scores correspond to a lower sense of well-being
(27).
Expectations about and experiences with
insulin therapy questionnaires
Input from the U.S. Food and Drug Administration
regarding the clinical trial plan for inhaled insulin
necessitated the immediate development of an assess-
ment of patients’ expectations about insulin therapy
for inclusion in the randomised clinical trial. There-
fore, the traditional approach for item generation
(qualitative study followed by item generation and
cognitive debrieﬁng) was not possible. Item genera-
tion was instead based on quantitative and qualita-
tive studies that have described the fears and
concerns about insulin therapy of individuals with
type 2 diabetes (14–22), or have reported the drivers
of patient satisfaction with and preference for diabe-
tes treatment (28). Fifteen items were developed: ﬁve
items (two positively worded and three negatively
worded) concerning insulin therapy in general
(Table 4); ﬁve items (four positively worded and one
negatively worded) concerning insulin delivery
systems (Table 4); and ﬁve positively worded items
to assess self-efﬁcacy (the participant’s conﬁdence in
achieving certain outcomes using insulin therapy,
such as consistently avoid high blood sugars when
taking insulin).
The EAITQ contains the 10 items concerning insu-
lin therapy and insulin delivery systems, all of which
are preceded by ‘I expect that….’, as well as the ﬁve
self-efﬁcacy items, which are preceded by ‘I am
conﬁdent that I will be able to….’ The response set
for all 15 items (including the ﬁve self-efﬁcacy items)
was a 7-point scale ranging from 1 (strongly
disagree) to 7 (strongly agree).
The EWITQ contains the same 10 items concern-
ing insulin therapy and insulin delivery systems as
the EAITQ, but the directions ask the respondent to
refer to his or her experiences with insulin therapy
in the past 4 weeks, and the items are stated in the
present tense. For example, the EWITQ item, ‘Taking
insulin makes me feel better’, corresponds to the
EAITQ item, ‘I expect that taking insulin will make
me feel better’. The EWITQ also contains the ﬁve
self-efﬁcacy questions, the wording of which is
identical to that in the EAITQ.
To conﬁrm that the 15 EAITQ items and the
corresponding 15 EWITQ items covered content that
was relevant to patients with type 2 diabetes, four
focus groups were conducted with 27 patients receiv-
ing diabetes treatment from clinics in either Hous-
ton, Texas or Seattle, Washington. Participants who
were not receiving injectable medications (n = 16,
62% males, 63% non-white, mean age = 50 years,
mean diabetes duration = 8 years) were asked about
their expectations regarding the possibility of needing
to take injectable medications in the future. Partici-
pants who were currently taking injectable insulin
(n = 11, 39% males, 45% non-white, mean
age = 55 years, mean diabetes duration = 17 years)
were asked how their expectations about having to
take injectable medications differed from their expe-
riences. The focus group results provided conﬁrma-
tion that items of the EAITQ and the EWITQ are
representative of the concepts expressed by patients
regarding their insulin therapy expectations and cor-
responding experiences, and have importance and
relevance to that patient population.
A preliminary validation study was also conducted
to examine factor structure, validity and reliability.
This study included 294 participants (mean
age = 60 years, 48% male, 67% Caucasian) from the
US. The EAITQ and EWITQ demonstrated good
internal reliability (Cronbach a = 0.82 and 0.79,
respectively) as well as convergent and discriminant
validity.
For the purposes of this study, the self-efﬁcacy
questions in the EAITQ and EWITQ were analysed
as a separate subscale (Self-Efﬁcacy subscale) with
Cronbach’s alpha = 0.87 at baseline and 0.88 at end-
point. For the other 10 items of the EAITQ and
EWITQ, a single measure of expectations and experi-
ences was desired. Therefore, the negatively worded
items on the two questionnaires were reverse-scored
so that higher scores on both positively worded and
negatively worded items corresponded to more posi-
tive expectations or experiences. Internal consistency
coefﬁcients (Cronbach’s alpha) for the 10 expecta-
tions and corresponding experience items were 0.80
and 0.72, respectively.
Statistical analyses
To test the differences between baseline values and
end-point values, t-tests for dependent samples were
performed. To address Research Question 1 regard-
ing correlates of expectations about insulin therapy,
Pearson correlation coefﬁcients were calculated
between EAITQ scores, patient characteristics [age,
duration of diabetes, gender, body mass index
(BMI)], baseline PRO scores (DTSQs, DSC-R sub-
scales, W-BQ12 subscales and Self-Efﬁcacy subscale)
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experiences with insulin therapy, Pearson correlation
coefﬁcients were also calculated between EWITQ
scores, patient characteristics, end-point PRO scores,
end-point A1c and EAITQ scores.
To address Research Question 2 regarding the
comparison of expectations about and experiences
with insulin therapy, the Wilcoxon Signed Rank test
for differences in dependent samples was performed
for all 10 expectation items and the corresponding
experience items. This non-parametric approach was
utilised because comparisons were between variables
with three discrete levels.
To address Research Question 3 concerning the
extent to which expectations about insulin therapy
were met by experiences with insulin therapy, the
EAITQ score was ﬁrst subtracted from the EWITQ
score to yield a difference score. Secondly, the SEM
for the difference score was calculated by multiplying
the standard deviation for the difference score by the
square root of 1-reliability of the difference score.
Difference scores were then used to categorise how
expectations were met by experiences. If the differ-
ence score was zero, plus or minus one SEM of dif-
ference score, expectations were met by experience. If
the difference score was greater than zero plus one
SEM, expectations were exceeded by experience. If
the difference score was less than zero minus one
SEM, expectations were not met by experience. One-
way analysis of variance with Scheffe post hoc tests
were performed to detect whether the DTSQs scores
of these three groups differed. Because of the number
of analyses performed, alpha was set at p < 0.01. Cal-
culations were computed with SPSS version 17.0
software.
Results
The study population consisted of 240 of the 303
completers of the clinical trial for whom data for
both EAITQ and EWITQ were obtained. Sixty-one
per cent of the study population was male, mean age
was 58 years, average length of diabetes diagnosis
was 10 years, and average BMI was 32 (Table 1).
Forty-four per cent of participants were from U.S.
clinical sites.
Across the study arms, from baseline to end-point,
signiﬁcant (p < 0.001) decreases were seen in study
participants’ mean A1c, perceived hyperglycaemia
score, hyperglycaemia symptoms score and negative
well-being (Table 2). Signiﬁcant (p < 0.001) increases
were observed in diabetes treatment satisfaction, self-
efﬁcacy and perceived hypoglycaemia score. There
were no signiﬁcant (p < 0.01) changes from baseline
in positive well-being or energy (Table 2).
Research Question 1: What are the correlates
of expectations about and experiences with
insulin therapy?
Table 3 presents correlations between EAITQ scores
and baseline patient characteristics and PRO assess-
ments, between EWITQ scores and baseline patient
characteristics and end-point PRO assessments, and
correlations between EAITQ and EWITQ scores are
also presented. The sample size of 240 could detect a
correlation between variables of ± 0.246 with 90%
power (two-tailed test, type 1 error rate of 0.01). A sig-
niﬁcant relationship (p < 0.01) was detected between
EAITQ scores and baseline Self-Efﬁcacy subscale
scores, with more positive expectations associated with
greater self-efﬁcacy. No other signiﬁcant relationships
were detected between EAITQ scores and patient char-
acteristics or baseline PRO assessments.
Signiﬁcant relationships (p < 0.01) were found
between EWITQ scores and the following patient
characteristics and end-point PRO assessments: diabe-
tes duration, with more positive experiences associated
with shorter diabetes duration; DTSQs Satisfaction
and DTSQs Perceived Hyperglycaemia scores, with
more positive experiences associated with greater
diabetes treatment satisfaction and lower perceived
hyperglycaemia; DSC-R psychological subscale scores,
with more positive experiences associated with less
symptom distress; W-BQ12 Negative Well-Being,
Energy and Positive Well-Being scores, with more
positive experiences associated with greater well-being;
and Self-Efﬁcacy scores, with more positive experi-
Table 1 Study population characteristics at baseline
(n = 240)
Characteristic Mean (SD)
Age (years) 57.8 (9.6)
Diabetes duration (years) 10.1 (7.0)
Body mass index (kg⁄m
2) 31.9 (5.8)
Per cent of study population
Male 61.3
Caucasian 77.9
African American 2.1
Hispanic 15.0
East Asian 1.3
West Asian 3.8
Country of clinical site
Argentina 13.8
Austria 3.3
Belgium 9.6
Spain 15.0
France 2.9
India 3.8
Mexico 7.5
United States 44.2
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tions. EWITQ scores were also signiﬁcantly associated
with EAITQ scores with correlation at r = 0.33 and
r-squared of 11%. These results suggest that more
positive experiences are associated with more positive
expectations and anticipation.
Research Question 2: How do the item
frequency distributions of expectations differ
from experiences in individuals with type 2
diabetes who are insulin-naı ¨ve and who
subsequently experience an inhaled insulin?
Signiﬁcant differences (p £ 0.001) were observed
between EAITQ and EWITQ item distributions
(Table 4) for all but two items, ‘Taking insulin will
cause me to gain an undesirable amount of weight’,
and ‘My insulin delivery system will not be noticed
by others when I use it’. For the positively worded
items, experiences were signiﬁcantly more positive
than expectations. For the negatively worded items,
experiences were signiﬁcantly less negative than
expectations.
Research Question 3: How does diabetes
treatment satisfaction differ among those
individuals whose expectations about insulin
therapy are exceeded by experiences with
insulin therapy when compared with those
whose expectations are met or those whose
expectations are not met?
The reliability coefﬁcient calculated for the expecta-
tions to experience change scores was 0.69 and the
standard deviation was 9.4. Therefore, the SEM for
the change scores was 0.5. When change scores were
calculated for each patient, 58% of patients had a
change score ‡ 0.5, indicating expectations were
exceeded by experience, 29% had a change score
within one SEM of zero (expectations were met by
experience); and 13% had change scores £ )0.5
(expectations were not met by experience). A signiﬁ-
cant difference in means was found between the
three groups. Post hoc tests indicated that the mean
DTSQ scores of all three groups (33, 29 and 26,
respectively) were signiﬁcantly different from each
other (Figure 1).
Discussion
The primary objective of this study was to identify
the relationships among expectations about insulin
therapy, experiences with insulin therapy, and diabe-
tes treatment satisfaction in a sample of insulin-naı ¨ve
patients with type 2 diabetes who experienced an
insulin therapy. The insulin therapy was an inhaled
insulin and expectations, experiences and diabetes
treatment satisfaction were assessed using three
validated questionnaires: EAITQ, EWITQ and DTSQ,
respectively.
Expectations about insulin therapy had a signiﬁ-
cant relationship with only one of the variables
explored: Self-efﬁcacy. More positive experiences
with insulin therapy were signiﬁcantly associated
with shorter duration of diabetes, less symptom dis-
tress, and greater well-being, self-efﬁcacy and treat-
Table 2 Baseline and end-point A1c and patient-reported outcomes scores (n = 240)
N Baseline mean (SD) End-point mean (SD)
A1c (%) 236 8.4 (1.0) 6.9 (0.8)*
DTSQs subscale (score minimum, maximum)
Satisfaction (0,36) 237 25.5 (7.3) 30.9 (5.5)*
Perceived hyperglycaemia (0,6) 240 3.9 (1.7) 2.0 (1.6)*
Perceived hypoglycaemia (0,6) 240 1.1 (1.6) 1.7 (1.5)*
DSC-R subscales
Hypoglycaemia (0,5) 237 1.3 (1.1) 1.1 (1.1)
Hyperglycaemia (0,5) 238 1.5 (1.1) 1.2 (1.1)*
Psychological (0,5) 238 1.5 (1.0) 1.3 (1.0)*
W-BQ subscales
Negative well-being (0,12) 238 2.1 (2.5) 1.5 (2.0)*
Energy (0,12) 235 7.4 (2.4) 7.6 (2.5)
Positive well-being (0,12) 237 8.4 (2.7) 8.5 (2.8)
EAITQ, EWITQ self-efﬁcacy subscale (1,7) 239 5.5 (1.0) 5.7 (1.0)*
*p < 0.01 compared with baseline; lower scores represent less perceived hyperglycaemia or hypoglycaemia, negative well-being, or
symptom burden. DSC-R, diabetes symptoms checklist-revised; DTSQ, Diabetes Treatment Satisfaction Questionnaire Status Version;
EAITQ, Expectations About Insulin Therapy Questionnaire; EWITQ, Experience With Insulin Therapy Questionnaires; W-BQ, Well-Being
Questionnaire.
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tation of conﬁdence in one’s abilities to achieve
certain outcomes [e.g. avoid high blood sugars with
insulin treatment (28)] may lead to more positive
experiences and subsequently better treatment satis-
faction. Prior research among patients with type 2
diabetes has shown that self-efﬁcacy and outcome
expectations correlate with self-care behaviours and
clinical outcomes independently (4,7–13,29). How-
ever, those studies did not evaluate how these con-
structs correlate with overall experiences and
treatment satisfaction.
Overall, patient experiences with insulin were sig-
niﬁcantly more positive than their expectations about
initiating therapy, with the exception of two items:
the expectation and experience of undesirable weight
gain with insulin therapy, and whether the insulin
delivery system would be noticeable to others. It is
well recognised that patients with type 2 diabetes
tend to gain weight when using insulin (15), with
16-week average gains of 0.5–6 kg for injectable
(30–32) and 2.7 kg for inhaled (33) insulin. Patients
in this study tended not to have any preconceived
expectation about gaining weight after treatment ini-
tiation, nor did they perceive their weight gain with
insulin therapy to be undesirable, even though the
average change in weight was 2 kg during the study
period (24). It must be recognised that patient
expectations may be based on past experience with
oral diabetes medications, which are typically not
associated with weight gain. Additionally, the extent
of weight gain that is undesirable will be based on
the individual’s perception (15) and what is undesir-
able may only become apparent with prolonged use
of insulin. Therefore, it is important for clinicians to
manage patient expectations about weight gain and
educate them on the ways to avoid undesirable
weight gain.
There was also no signiﬁcant difference between
expectations and experience concerning whether
patients expected and experienced the use of their
insulin delivery system to be noticed by others.
Discreteness of insulin delivery system has been shown
to be rated as an important attribute of such systems
by patients with type 2 diabetes (34) and has been
suggested as a driver of insulin delivery system satis-
faction and⁄or preference (35). Although patients
may have had experience with family or friends who
take insulin injections and base their expectations
about the discreteness of an injection on that experi-
ence, it is unlikely that most had any experience with
inhaled insulin on which to base expectations of
discreteness. At the time of the study, only one
inhaled insulin was on the market in the United
States and it had been available for a relatively short
time. No inhaled insulin was on the market in other
study countries. Given that the inhaled insulin was
used at mealtime, it is possible that patients found
themselves in the presence of others when they
needed to administer a dose. Therefore, the EWITQ
item distribution may suggest that ‘others’ noticed a
patient using their system, but that the attention was
not a source of sufﬁcient embarrassment or discom-
fort to lead a large proportion of patients to disagree
that the system would ‘not be noticed by others
when I use it’.
This study showed that a large proportion of
patients’ expectations were exceeded by their very
positive experiences with an inhaled insulin. Previous
research has shown associations between symptom
reduction, greater well-being and satisfaction with
initiation of insulin (36,37). In the current study, sta-
tistically signiﬁcant and clinically meaningful differ-
ences in diabetes treatment satisfaction were
Table 3 Correlations between EAITQ or EWITQ Scores
and patient characteristics and patient-reported
outcomes at baseline and end-point
Correlation
with EAITQ
score
Correlation
with EWITQ
score
EAITQ score – 0.33*
Age )0.11 )0.11
Diabetes duration )0.08 )0.20*
Body mass index 0.04 )0.10
Baseline End-point
A1c 0.04 0.03
DTSQs subscales
Diabetes treatment
satisfaction
0.11 0.53*
Perceived hyperglycaemia 0.09 )0.23*
Perceived hypoglycaemia )0.10 )0.13
DSC-R subscales
Hypoglycaemia )0.04 )0.13
Hyperglyacemia 0.05 )0.07
Psychological )0.04 )0.20*
W-BQ subscales
Negative well-being )0.13 )0.17*
Energy 0.17 0.30*
Positive well-being 0.14 0.42*
EAITQ⁄EWITQ self-efﬁcacy 0.46* 0.56*
*p < 0.01; lower scores represent less perceived hyperglyca-
emia or hypoglycaemia, negative well-being, or symptom
burden. DSC-R, diabetes symptoms checklist-revised; DTSQ,
Diabetes Treatment Satisfaction Questionnaire Status Version;
EAITQ, Expectations About Insulin Therapy; EWITQ, Experience
With Insulin Therapy Questionnaires; W-BQ, Well-Being
Questionnaire.
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not differ in baseline characteristics) based on the
relationship between their expectations and their
experiences. In general, it has been shown that treat-
ment satisfaction scores among patients with type 2
diabetes, as measured by the DTSQs, increase one to
two points from baseline to end-point after treat-
ment initiation (36,38,39). Strikingly, diabetes treat-
ment satisfaction scores in this study increased an
average of ﬁve points from baseline to end-point.
This study included approximately 20% less cases
than clinical trial results as a result of the unavail-
ability of linguistic validations of the EAITQ and
EWITQ in the primary language spoken at several
study sites. Results of this study are consistent with
those found by Kumar (7), suggesting that compara-
ble ﬁndings would be attained with larger sample
sizes. Additional limitations to this study include that
patients enrolling in a clinical trial moreover, indi-
viduals who completed the clinical trial and for
whom EAITQ and EWITQ data were available both
at baseline and endpoint, may not necessarily be rep-
resentative of all patients with type 2 diabetes, and
expectations and experiences of these patients regard
an inhaled insulin delivery system and may not apply
to injectable insulin delivery systems.
Implications for diabetes educators
Using validated patient-reported outcomes measures
such as the EAITQ and EWITQ in clinical research
may help identify differences between expectations
and experiences and determine what drives individ-
ual satisfaction or preference. Use of these question-
naires within clinical practice may help clinicians
Table 4 Response distributions for EAITQ and EWITQ
EAITQ response
distribution (%)
EWITQ response
distribution (%)
DA-SDA SIDA-SIA A-SA DA-SDA SIDA-SIA A-SA
Taking insulin will…
make it easier to control my blood sugars.* 1 38 61 3 12 85
restrict my life.* 31 55 14 56 31 13
Cause me to have severe episodes of low blood sugar.* 19 72 9 50 44 7
make me feel better.* 2 49 50 5 26 68
Cause me to gain an undesirable amount of weight. 19 72 9 34 41 25
My insulin delivery system will…
be physically painful.* 38 54 8 83 10 7
be easy for me to use away from home.* 5 51 45 7 20 74
not be noticed by others when I use it. 10 65 25 16 46 38
It will be easy to get the insulin dose I need with my IDS. * 2 54 44 3 14 83
My insulin delivery system will be convenient. * 4 50 46 3 18 79
*p £ 0.001 end-point compared with baseline. A, agree; DA, disagree; IDS, insulin delivery system; SA, strongly agree; SDA, strongly
disagree; SIA, slightly agree; SIDA, slightly disagree.
Figure 1 Differences in Diabetes Treatment Satisfaction Scores based on the extent to which patients’ expectations about
insulin therapy are exceeded by experiences
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insight into the degree to which patient expectations
about insulin therapy may be fulﬁlled through their
experiences and how these factors correlate to overall
treatment satisfaction.
As patients begin to think about insulin therapy, it
may be more advantageous for clinicians to explore
patient expectations than to examine barriers to
treatment initiation. Individual perceptions may be
inﬂuenced through education and counselling more
readily than a barrier comprised of multiple factors.
Diabetes educators may use the EAITQ as a tool to
assist in identifying patients with type 2 diabetes who
have unrealistically positive or negative expectations
about initiating treatment. These expectations can
then be managed prior to initiating insulin therapy
to achieve more positive experiences, better treat-
ment satisfaction, improvements in compliance and
willingness to continue treatment and, ultimately,
improved outcomes.
Clinical trials registration
This study was funded by Eli Lilly and Company and
is related to clinical trial NCT00391209, ClinicalTri
als.gov.
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